What is Lipofen?
Lipofen (Lipofen) helps reduce cholesterol and triglycerides (fatty acids) in the blood. High levels of these types of fat in the blood are associated with an increased risk of atherosclerosis (clogged arteries).
Lipofen is used to treat high cholesterol and high triglyceride levels.
Lipofen may also be used for purposes not listed in this medication guide.
Lipofen indications
Primary Hypercholesterolemia or Mixed Dyslipidemia
Lipofen Capsules are indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (total-c), Triglycerides (TG) and apolopoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia.
Severe Hypertriglyceridemia
Lipofen Capsules are also indicated as adjunctive therapy to diet for treatment of adult patients with severe hypertriglyceridemia. Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacologic intervention.
Markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of Lipofen therapy on reducing this risk has not been adequately studied.
Important Limitations of Use
Lipofen at a dose equivalent to 150 mg was not shown to reduce coronary heart disease morbidity and mortality in 2 large, randomized controlled trials of patients with type 2 diabetes mellitus.
How should I use Lipofen?
Use Lipofen capsules as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Some brands of Lipofen capsules should be taken with food. Some brands may be taken with or without food. Ask your pharmacist if you should take your brand of Lipofen capsules with food.
- Swallow Lipofen capsules whole. Do not open, crush, dissolve, or chew before swallowing. If you cannot swallow Lipofen capsules whole, tell your doctor. You may need a different medicine.
- Take Lipofen capsules with a full glass of water (8 oz [240 mL]).
- If you also take a bile acid-binding resin (eg, cholestyramine), do not take it within 4 to 6 hours before or 1 hour after taking Lipofen capsules. Check with your doctor if you have any questions.
- Take Lipofen capsules on a regular schedule to get the most benefit from it.
- Taking Lipofen capsules at the same time each day will help you remember to take it.
- Continue to take Lipofen capsules even if you feel well. Do not miss any doses.
- If you miss a dose of Lipofen capsules, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Lipofen capsules.
Uses of Lipofen in details
Use: Labeled Indications
Hypercholesterolemia or mixed dyslipidemia: Adjunctive therapy to diet for the reduction of low-density lipoprotein cholesterol (LDL-C), total cholesterol (total-C), triglycerides, and apolipoprotein B (apo B), and to increase high-density lipoprotein cholesterol (HDL-C) in adults with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson types IIa and IIb). Use lipid-altering agents in addition to a diet restricted in saturated fat and cholesterol when response to diet and nonpharmacological interventions alone has been inadequate.
Note: While FDA-approved for hypercholesterolemia, Lipofen is not a first- or second-line choice; other agents may be more suitable (ACC/AHA [Stone 2013]). In addition, use is not recommended to lower LDL-C or raise HDL-C in the absence of hypertriglyceridemia.
Hypertriglyceridemia: Adjunctive therapy to diet for treatment of adult patients with severe hypertriglyceridemia (Fredrickson types IV and V hyperlipidemia).
Off Label Uses
Primary biliary cholangitis
Data from a single-center, retrospective cohort study support the use of Lipofen (in combination with ursodiol) in patients with primary biliary cholangitis (PBC) who have had an incomplete biochemical response to ursodiol monotherapy and showed significant improvement in alkaline phosphatase, a reduction in hepatic decompensation, and transplant-free survival improvement.
Lipofen description
Each film-coated tablet contains Fenofibrate BP 160 mg. It also contains the following excipients: Pregelatinized starch maize, povidone, sodium lauryl sulphate, microcrystalline cellulose, crospovidone, anhydrous colloidal silica, sodium stearyl fumarate, purified water and opadry AMB OY-B-28920.
Lipofen is a lipid-regulating agent. The empirical formula is C20H21O4Cl and the molecular weight is 360.83. Lipofen is 2-[4-(4-chlorobenzoyl) phenoxy]-2-methyl-propanoic acid, 1-methylethyl ester.
Lipofen dosage
Lipofen Dosage
Generic name: Lipofen 160mg
Dosage form: tablet
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
The dose of Lipofen is 160 mg once daily.
Patients should be placed on an appropriate lipid-lowering diet before receiving Lipofen and should continue this diet during treatment with Lipofen.
Lipid levels should be monitored periodically. Therapy should be withdrawn in patients who do not have an adequate response after two months of treatment.
Lipofen tablets can be given without regard to meals. Patients should be advised to swallow Lipofen tablets whole. Do not crush, break, dissolve, or chew tablets.
More about Lipofen (Lipofen)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Espanol
- 0 Reviews - Add your own review/rating
Consumer resources
- Lipofen
- Lipofen (Advanced Reading)
- Other brands: Lipofen, Lofibra, Lipofen, Lipofen, More (1) »
Professional resources
- Lipofen (FDA)
- Fenofibric Acid/Lipofen (AHFS Monograph)
Related treatment guides
- Hyperlipoproteinemia
- Hyperlipoproteinemia Type IIa, Elevated LDL
- Hyperlipoproteinemia Type IIb, Elevated LDL VLDL
- Hyperlipoproteinemia Type IV, Elevated VLDL
- Hyperlipoproteinemia Type V, Elevated Chylomicrons VLDL
- More (1) »
Lipofen interactions
See also:
What other drugs will affect Lipofen?
Coumarin Anticoagulants
Potentiation of coumarin-type anticoagulant effect has been observed with prolongation of the PT/INR.
Caution should be exercised when Lipofen is given in conjunction with coumarin anticoagulants. Lipofen may potentiate the anticoagulant effect of these agents resulting in prolongation of the PT/INR. To prevent bleeding complications, frequent monitoring of PT/INR and dose adjustment of the oral anticoagulant as recommended until the PT/INR has stabilized.
Immunosuppressants
Immunosuppressant agents such as cyclosporine and tacrolimus can impair renal function and because renal excretion is the primary elimination route of fibrate drugs including Lipofen capsules, there is a risk that an interaction will lead to deterioration of renal function. When immunosuppressants and other potentially nephrotoxic agents are co-administered with Lipofen capsules, the lowest effective dose of Lipofen capsules should be employed and renal function should be monitored.
Bile-Acid Binding Resins
Since bile-acid binding resins may bind other drugs given concurrently, patients should take Lipofen at least 1 hour before or 4 to 6 hours after a bile acid binding resin to avoid impeding its absorption.
Colchicine
Cases of myopathy, including rhabdomyolysis, have been reported with fenofibrates co-administered with colchicine, and caution should be exercised when prescribing Lipofen with colchicine.
Lipofen side effects
See also:
What are the possible side effects of Lipofen?
Clinical Trials Experience
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.
Fenofibric acid is the active metabolite of Lipofen. Adverse events reported by 2% or more of patients treated with Lipofen and greater than placebo during double-blind, placebocontrolled trials are listed in Table 1. Adverse events led to discontinuation of treatment in 5.0% of patients treated with Lipofen and in 3.0% treated with placebo. Increases in liver tests were the most frequent events, causing discontinuation of Lipofen treatment in 1.6% of patients in double-blind trials.
Table 1: Adverse Events Reported by 2% or More of Patients Treated with Lipofen and Greater than Placebo During the Double-Blind, Placebo-Controlled Trials
| BODY SYSTEM Adverse Event | Lipofen* (N = 439) | Placebo (N = 365) |
| BODY AS A WHOLE | ||
| Abdominal Pain | 4.6% | 4.4% |
| Back Pain | 3.4% | 2.5% |
| Headache | 3.2% | 2.7% |
| DIGESTIVE | ||
| Nausea | 2.3% | 1.9% |
| Constipation | 2.1% | 1.4% |
| INVESTIGATIONS | ||
| Abnormal Liver Tests | 7.5% | 1.4% |
| Increased AST | 3.4% | 0.5% |
| Increased ALT | 3.0% | 1.6% |
| Increased Creatine Phosphokinase | 3.0% | 1.4% |
| RESPIRATORY | ||
| Respiratory Disorder | 6.2% | 5.5% |
| Rhinitis | 2.3% | 1.1% |
| * Dosage equivalent to 135 mg Lipofen |
Clinical trials with Lipofen did not include a placebo-control arm. However, the adverse event profile of Lipofen was generally consistent with that of Lipofen. The following adverse events not listed above were reported in ≥ 3% of patients taking Lipofen alone:
Gastrointestinal Disorders: Diarrhea, dyspepsia
General Disorders and Administration Site Conditions: Pain
Infections and Infestations: Nasopharyngitis, sinusitis, upper respiratory tract infection
Musculoskeletal and Connective Tissue Disorders: Arthralgia, myalgia, pain in extremity
Nervous System Disorders: Dizzinesss
Postmarketing Experience
The following adverse events have been identified during postapproval use of Lipofen: rhabdomyolysis, pancreatitis, renal failure, muscle spasms, acute renal failure, hepatitis, cirrhosis, anemia, asthenia, and severely depressed HDL-cholesterol levels.
Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Lipofen contraindications
See also:
What is the most important information I should know about Lipofen?
Hypersensitivity to Lipofen or fenofibric acid or to any of the excipients of Lipofen.
Severe renal impairment/insufficiency, including those receiving dialysis.
Active liver disease/dysfunction/insufficiency, including those with primary biliary cirrhosis and unexplained persistent liver function abnormalities eg, persistent elevations in serum transaminases. Pre-existing gallbladder disease.
Photoallergy or phototoxic reaction during treatment with fibrates or ketoprofen.
Chronic or acute pancreatitis with the exception of acute pancreatitis due to severe hypertriglyceridemia.
Lipofen contains lecithin soya as an excipient and therefore, Lipofen should not be taken with allergic to peanut or arachis oil or soya lecithin, or related products due to the risk of hypersensitivity reactions.
Use in lactation: Lipofen should not be used in nursing mothers. Because of the potential for tumorigenicity seen in animal studies, a decision should be made whether to discontinue nursing or to discontinue Lipofen, taking into account the importance of Lipofen to the mother. There are no data on the excretion of Lipofen and/or its metabolites into breast milk.
Use in children: Safety and effectiveness in pediatric patients aged <18 years have not been established.
Active ingredient matches for Lipofen:
Fenofibrate in Portugal, Turkey, United States.
| Unit description / dosage (Manufacturer) | Price, USD |
| Capsule; Oral; Fenofibrate 100 mg | |
| Capsule; Oral; Fenofibrate 150 mg | |
| Capsule; Oral; Fenofibrate 50 mg | |
| 30 capsule in 1 bottle, plastic | |
| 90 capsule in 1 bottle, plastic | |
| Lipofen capsule 150 mg/1 (Kowa Pharmaceuticals America Inc. (US)) | |
| Lipofen capsule 50 mg/1 (Kowa Pharmaceuticals America Inc. (US)) | |
List of Lipofen substitutes (brand and generic names): | |
| Lipoclar (Italy) | |
| LIPOFEN SR | |
| Lipofen-SR (Turkey) | |
| Lipofene (Italy) | |
| Lipofib (Romania) | |
| Lipohexal (Czech Republic) | |
| Lipolex (Egypt) | |
| Lipomax 105 (Argentina) | |
| Lipomax 35 (Argentina) | |
| Lipomin 100 | |
| Lipomin 300 | |
| Lipoplasmin (Argentina) | |
| Lipoprothyl (Taiwan) | |
| Lipoprothyl 160 mg | |
| Liposyr 100 | |
| Liposyr 300 | |
| Lipothin (Thailand) | |
| Lipothin 200 200 mg x 3 x 10's | |
| Lipozor 250 | |
| Lipsin (Austria, Italy) | |
| Capsule; Oral; Fenofibrate 100 mg (Aventis) | |
| Lipsin retard (Austria) | |
| Capsule; Oral; Fenofibrate 250 mg | |
| Liptuin (Argentina) | |
| Lipway (Philippines) | |
| Lipway SR 250 mg x 30's (Cathay) | $ 22.00 |
| Lipway SR (Philippines) | |
| Lipway SR MR cap 250 mg 30's (Cathay Drug) | $ 23.15 |
| Livesan (France) | |
| Lofat (Bangladesh) | |
| Lofibra | |
| 100 capsule in 1 bottle (Pharos) | |
| Lofibra 250 mg x 3 x 10's (Pharos) | $ 25.30 |
| Lofibra 200 mg x 50's (Pharos) | $ 22.02 |
| Lofibra capsule 200 mg/1 (Pharos) | |
| Lofibra tablet, film coated 54 mg/1 (Pharos) | |
| Lofibra capsule 67 mg/1 (Pharos) | |
| Lofibra tablet, film coated 160 mg/1 (Pharos) | |
| Lofibra capsule 134 mg/1 (Pharos) | |
| Lofibra Capsules | |
| Lopandil (South Korea) | |
| LOTGL (India) | |
| 200 mg x 10's (Grandix) | $ 0.59 |
| Lotgl 200mg TAB / 10 (Grandix) | $ 0.59 |
| LOTGL 200MG TABLET 1 strip / 10 tablets each (Grandix) | $ 0.67 |
| LOTGL tab 200 mg x 10's (Grandix) | $ 0.59 |
| Lotgl 200mg TAB / 10 (Grandix) | $ 0.59 |
| Lotgl 200mg Tablet (Grandix) | $ 0.07 |
| Lowlip (Taiwan) | |
| Lowlip 20 mg x 3 Blister x 10 Tablet (Medikon) | |
| Lowlip 40 mg x 3 Blister x 10 Tablet (Medikon) | |
See 1098 substitutes for Lipofen | |
References
- DailyMed. "FENOFIBRATE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "fenofibrate". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "fenofibrate". http://www.drugbank.ca/drugs/DB01039 (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Lipofen are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Lipofen. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
